Tailored tumor attack: can custom drug cocktails beat recurrent glioblastoma?

NCT ID NCT03681028

Completed Disease control Sponsor: Jennifer Clarke Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether it's possible to quickly create and start a personalized drug combination for each patient with recurrent glioblastoma, a serious brain cancer. Researchers used genetic testing on tumor tissue to pick drugs that target specific mutations. The study enrolled 30 adults whose tumors could be surgically removed, and measured how many could start their custom treatment within 35 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: individualized combination of drugs based on genetic testing
What this could lead to: If successful, this approach could show that tailoring treatment to a patient's tumor genetics is feasible and may improve outcomes for recurrent glioblastoma.
What could go wrong: This is a very early, small pilot study (30 people) testing feasibility, not effectiveness. Many personalized regimens may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

University of California San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.